Methods and compositions for localized agent delivery
AssigneeMassachusetts Institute of Technology
InventorsDarrell J. Irvine, Matthias Stephan, Jaehyun Moon, Anna Bershteyn
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for delivering agents to localized regions, tissues, or organs in vivo by conjugating agent-loaded nanoparticles to cells having homing capability. The agents may be therapeutic or diagnostic agents such as cancer chemotherapeutic agents and imaging agents respectively.
Claims25
A method for maintaining, stimulating or enhancing activity of a T cell, comprising administering to a subject a T cell that homes to a tumor and is covalently bound to a synthetic nanoparticle that comprises an immunostimulatory cytokine that maintains, stimulates or enhances activity of a T cell, wherein the T cell does not significantly internalize the synthetic nanoparticle and maintains the synthetic nanoparticle on the cell surface, and wherein release of the immunostimulatory cytokine from the synthetic nanoparticle maintains, stimulates or enhances activity of the T cell relative to an unmodified T cell.
A composition comprising a T cell that homes to a tumor and is covalently bound to a synthetic nanoparticle that comprises an immunostimulatory cytokine that maintains, stimulates or enhances activity of a T cell, wherein the T cell does not significantly internalize the synthetic nanoparticle and maintains the synthetic nanoparticle on the cell surface, and wherein release of the immunostimulatory cytokine from the synthetic nanoparticle maintains, stimulates or enhances activity of the T cell relative to an unmodified T cell.
A method of maintaining, stimulating or enhancing activity of a T cell, comprising administering to a subject a population of T cells that home to a tumor and are covalently bound to a plurality of synthetic nanoparticles that comprise an immunostimulatory cytokine that maintains, stimulates or enhances activity of a T cell, wherein the T cells do not significantly internalize the synthetic nanoparticles and maintains the synthetic nanoparticles on the cell surface, and wherein release of the immunostimulatory cytokine from the synthetic nanoparticles maintains, stimulates or enhances activity of the T cells relative to unmodified T cells.
Dependencies are inferred from the claim text.